Navigation Links
UM researchers find new marker to identify cancer stem cells

ANN ARBOR, Mich. Researchers at the University of Michigan Comprehensive Cancer Center have found a marker that can be used to identify stem cells in breast tumors, suggesting a potential simple test that could help determine the best treatment for breast cancer.

The finding also provides strong support for the hypothesis that a small number of cells, called cancer stem cells, are responsible for fueling a tumors growth.

U-M researchers were the first to discover stem cells in a solid tumor, finding them first in breast cancer. Generally, stem cells make up fewer than 5 percent of all the cells in a tumor, but they may be the key cells in cancer progression. The process of looking at the cell surface to identify stem cells, however, is too complex to apply to patient care.

In the new study, published in the November issue of Cell Stem Cell, the researchers found that cells from normal and cancerous breast tissue that had high levels of the enzyme aldehyde dehydrogenase activity, or ALDH, acted like breast stem cells. Further, of 577 human breast cancer tissue samples studied, those that expressed the specific form ALDH1 had the worst outcomes, suggesting this easily detected marker could be used to assess prognosis.

This study is a big step because it provides a marker thats easy to use in both normal and cancer cells. Clinical applications were really not possible with the previously described markers. The fact that ALDH1 was identified in stem/progenitor cells from both normal and cancer tissue lends support to the idea that those cells are the primary target of transformation to malignancy. We believe it is only a very small population of cells that really are capable of unlimited growth and therefore drive cancer recurrence and metastasis, says senior study author Gabriela Dontu, M.D., Ph.D., research assistant professor of internal medicine at the U-M Medical School.

Researchers used a reagent called ALDEFLUOR to detect the ALDH activity in the cells. Cells with high levels of this enzyme become fluorescent and can be detected. Cells can then be sorted to pull out the stained cells.

When they did this, researchers found that the ALDEFLUOR-positive cells acted like stem cells, while the ALDEFLUOR-negative cells did not. Stem cells are defined by their ability to generate identical cells as well as to differentiate into other types of cells.

The study also tested whether the separated cells could produce a breast tumor. Tumors formed only from the ALDEFLUOR-positive cells, even when as few as 500 cells were used. On the other hand, 50,000 ALDEFLUOR-negative cells did not generate tumors.

In addition to identifying the stem cells, the researchers found ALDH1 can indicate how aggressive a tumor is. In tissue samples from 577 patients with breast cancer, those bearing ALDH1-positive tumors had lower overall survival and were 1.76 times more likely to develop metastases than patients with ALDH1-negative tumors. ALDH1 was expressed in 19 percent to 30 percent of the tumors.

The ALDH1 marker correlates with more aggressive tumors, possibly reflecting a different rate of renewal of cancer stem cells in these cancers. Its possible to use ALDH1 in association with other markers as a prognostic marker to help determine what treatment is necessary. More research is needed, though, before we can apply these findings in the clinic, Dontu says.

While this work was done specifically in breast cancer, the researchers believe it could have implications for other cancer types. U-M researchers are actively involved in stem cell research in virtually all cancer types. In addition to the initial breast cancer stem cell discovery, U-M researchers have been the first to identify stem cells in pancreatic and head and neck cancers. Work is ongoing to develop and test treatments that target these cells.

The lessons weve learned from breast cancer stem cells have been very valuable to us as we attack the cancer stem cells in other organs. Our hope is that some of the treatments we develop for one type of tumor like breast cancer may also work in targeting the cancer stem cells in these other types of tumors, and so we actually may make great progress in treating a wide variety of cancers, says Max S. Wicha, M.D., Distinguished Professor of Oncology and Director of the U-M Comprehensive Cancer Center.

This research is still in the laboratory stage and no clinical tests or treatments are currently available. For information about currently available treatments, call the U-M Cancer AnswerLine at 800-865-1125 or visit


Contact: Nicole Fawcett
University of Michigan Health System

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
Breaking Biology Technology: